# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $12 price target.
HC Wainwright & Co. analyst Arthur He maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $10 to...
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.79) by 29...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...
The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their co...